



ASX Release

Quarterly Cash Flow Report and Trading Update

Quarter ended 30 September 2019

Melbourne, Australia; 31 October 2019: Melbourne, Australia; Jayex Healthcare Limited (ASX:JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms in the UK, Australia and New Zealand, today released its Appendix 4C - Quarterly cash flow report for the quarter ended 30 September 2019 (the **Quarter**).

- Receipts from customers for the quarter \$2,357,000 (up 73% on the same period last year. Q3, 2018 \$1,363,000).
- Net Profit for the UK operations up until 30 September 2019 \$754,000 (up 35% on same period last year January to September 2019 \$559,000).
- Australian Sales operation breaking even.
- 13 SurgeryPod systems sold with a total sales revenue of \$160,000.
- Medical Cannabis research licence for the Papamoa, New Zealand facility expected Q4, 2019.

Operationally the Company continues to deploy its technologies of *Appointuit* (patient engagement) and *Patient Flow Management* platforms, *Enlighten* and *Arrive* (patient arrival registration via kiosks, calling screens and way finding technologies) across the UK, Australia and New Zealand. With the continuing roll out of the *Jayex Connect* platform (increase from 649 active customers at the end of June 2019 to 717 active customers today), the Company is migrating from a Product company to a Software as a Service company (SaaS). The Company has invested in new infrastructure systems to support its planned migration to a SaaS company. In addition, the Company has undergone a re-structure program of the sales team in order to leverage the SaaS sales process more effectively.

Contacts for further information:

Chief Executive Officer
Nick Fernando
1300 330 611
n.fernando@jayex.com

Company Secretary
Melanie Leydin
0417 663 119

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

JAYEX HEALTHCARE LIMITED

ABN

15 119 122 477

Quarter ended ("current quarter")

30 September 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,357	6,937
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(695)	(1,539)
(c) advertising and marketing	(35)	(98)
(d) leased assets	-	-
(e) staff costs	(847)	(2,454)
(f) administration and corporate costs	(749)	(2,524)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(70)	(209)
1.6 Taxes paid	-	-
1.7 Other (provide details if material)	-	-
1.8 Net cash from / (used in) operating activities	(39)	113

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	100
3.6 Repayment of lease liabilities	(40)	(95)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	(40)	5

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	586	389
4.2 Net cash from / (used in) operating activities (item 1.8 above)	(39)	113
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(40)	5

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	507	507

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	507	586
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	507	586

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
-
-

Nil

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000
-
-

Nil

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	3,655	3,366
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Facility amount	Lender	Interest rate	Secured/unsecured
\$2,000,000	Covenant Holdings (WA) Pty Ltd	8% per annum	Unsecured
\$1,000,000	Covenant Holdings (WA) Pty Ltd	12% per annum	Unsecured
\$155,000	Covenant Holdings (WA) Pty Ltd	Interest free	Unsecured
\$500,000	Covenant Holdings (WA) Pty Ltd	Interest free	Unsecured


9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	(300)
9.3 Advertising and marketing	(25)
9.4 Leased assets	(40)
9.5 Staff costs	(800)
9.6 Administration and corporate costs	(800)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(1,965)

* Please note that the above estimated cash outflows for the next quarter do not include inflows of receipts from customers. The cash outflows are estimates only and variable outflows are calculated on forecast revenue for the quarter. Variable outflows will change if actual revenue differs from forecast revenue.

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Company secretary)

Date: 31 October 2019

Print name:MELANIE LEYDIN.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.